Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry

Victoria K. Shanmugam, Tracy M. Frech, Virginia D. Steen, Laura K. Hummers, Ami A. Shah, Elana J. Bernstein, Dinesh Khanna, Jessica K. Gordon, Flavia V. Castelino, Lorinda Chung, Faye N. Hant, Emily Startup, John M. VanBuren, Luke B. Evnin, Shervin Assassi

Research output: Contribution to journalArticle

Abstract

Abstract: The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. The data collection methodology incorporates successful models from other SSc registries. The cohort is designed to provide linked bio-specimen and clinical outcomes data on a longitudinal cohort of SSc patients for validation of hypothesis-driven research and to provide a platform for studying patient-reported outcomes in scleroderma. The CONQUER registry was developed using the guidelines of the International Society for Biological Repositories, and was an iterative process between physicians with an expertise in SSc, patient stakeholders, and information technology experts. Enrollment commenced in June 2018. During the first 6 months of the CONQUER Scleroderma study, 151 SSc patients with less than 5 years of disease duration (from first non-Raynaud’s symptom) have been recruited. The mean age is 51 ± 14 years, 83% are female, and 60% of patients have diffuse disease. Survey completion rates are above 88% for all patient-reported outcome surveys. Bio-specimen collection rates are over 97%, and disease severity score completion rates are over 98%. Pulmonary function test data is available on 91% of patients, and echocardiography is available 80%. The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. Key Points: • The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. • The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. • CONQUER is innovative in its design in that it is focused on prospective collection of paired clinical and patient outcome data with bio-specimens.

Original languageEnglish (US)
JournalClinical rheumatology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Systemic Scleroderma
Registries
Longitudinal Studies
Specimen Handling
Respiratory Function Tests
Population
Echocardiography
Guidelines
Technology
Physicians

Keywords

  • Bio-specimens
  • Cohort study
  • Patient-reported outcomes
  • Prospective study
  • Registry
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma : outcomes from a multicenter US-based systemic sclerosis registry. / Shanmugam, Victoria K.; Frech, Tracy M.; Steen, Virginia D.; Hummers, Laura K.; Shah, Ami A.; Bernstein, Elana J.; Khanna, Dinesh; Gordon, Jessica K.; Castelino, Flavia V.; Chung, Lorinda; Hant, Faye N.; Startup, Emily; VanBuren, John M.; Evnin, Luke B.; Assassi, Shervin.

In: Clinical rheumatology, 01.01.2019.

Research output: Contribution to journalArticle

Shanmugam, VK, Frech, TM, Steen, VD, Hummers, LK, Shah, AA, Bernstein, EJ, Khanna, D, Gordon, JK, Castelino, FV, Chung, L, Hant, FN, Startup, E, VanBuren, JM, Evnin, LB & Assassi, S 2019, 'Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry', Clinical rheumatology. https://doi.org/10.1007/s10067-019-04792-y
Shanmugam, Victoria K. ; Frech, Tracy M. ; Steen, Virginia D. ; Hummers, Laura K. ; Shah, Ami A. ; Bernstein, Elana J. ; Khanna, Dinesh ; Gordon, Jessica K. ; Castelino, Flavia V. ; Chung, Lorinda ; Hant, Faye N. ; Startup, Emily ; VanBuren, John M. ; Evnin, Luke B. ; Assassi, Shervin. / Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma : outcomes from a multicenter US-based systemic sclerosis registry. In: Clinical rheumatology. 2019.
@article{881212672a474647b9bc838bb03e2ccf,
title = "Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry",
abstract = "Abstract: The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. The data collection methodology incorporates successful models from other SSc registries. The cohort is designed to provide linked bio-specimen and clinical outcomes data on a longitudinal cohort of SSc patients for validation of hypothesis-driven research and to provide a platform for studying patient-reported outcomes in scleroderma. The CONQUER registry was developed using the guidelines of the International Society for Biological Repositories, and was an iterative process between physicians with an expertise in SSc, patient stakeholders, and information technology experts. Enrollment commenced in June 2018. During the first 6 months of the CONQUER Scleroderma study, 151 SSc patients with less than 5 years of disease duration (from first non-Raynaud’s symptom) have been recruited. The mean age is 51 ± 14 years, 83{\%} are female, and 60{\%} of patients have diffuse disease. Survey completion rates are above 88{\%} for all patient-reported outcome surveys. Bio-specimen collection rates are over 97{\%}, and disease severity score completion rates are over 98{\%}. Pulmonary function test data is available on 91{\%} of patients, and echocardiography is available 80{\%}. The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. Key Points: • The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. • The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. • CONQUER is innovative in its design in that it is focused on prospective collection of paired clinical and patient outcome data with bio-specimens.",
keywords = "Bio-specimens, Cohort study, Patient-reported outcomes, Prospective study, Registry, Systemic sclerosis",
author = "Shanmugam, {Victoria K.} and Frech, {Tracy M.} and Steen, {Virginia D.} and Hummers, {Laura K.} and Shah, {Ami A.} and Bernstein, {Elana J.} and Dinesh Khanna and Gordon, {Jessica K.} and Castelino, {Flavia V.} and Lorinda Chung and Hant, {Faye N.} and Emily Startup and VanBuren, {John M.} and Evnin, {Luke B.} and Shervin Assassi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10067-019-04792-y",
language = "English (US)",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma

T2 - outcomes from a multicenter US-based systemic sclerosis registry

AU - Shanmugam, Victoria K.

AU - Frech, Tracy M.

AU - Steen, Virginia D.

AU - Hummers, Laura K.

AU - Shah, Ami A.

AU - Bernstein, Elana J.

AU - Khanna, Dinesh

AU - Gordon, Jessica K.

AU - Castelino, Flavia V.

AU - Chung, Lorinda

AU - Hant, Faye N.

AU - Startup, Emily

AU - VanBuren, John M.

AU - Evnin, Luke B.

AU - Assassi, Shervin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Abstract: The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. The data collection methodology incorporates successful models from other SSc registries. The cohort is designed to provide linked bio-specimen and clinical outcomes data on a longitudinal cohort of SSc patients for validation of hypothesis-driven research and to provide a platform for studying patient-reported outcomes in scleroderma. The CONQUER registry was developed using the guidelines of the International Society for Biological Repositories, and was an iterative process between physicians with an expertise in SSc, patient stakeholders, and information technology experts. Enrollment commenced in June 2018. During the first 6 months of the CONQUER Scleroderma study, 151 SSc patients with less than 5 years of disease duration (from first non-Raynaud’s symptom) have been recruited. The mean age is 51 ± 14 years, 83% are female, and 60% of patients have diffuse disease. Survey completion rates are above 88% for all patient-reported outcome surveys. Bio-specimen collection rates are over 97%, and disease severity score completion rates are over 98%. Pulmonary function test data is available on 91% of patients, and echocardiography is available 80%. The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. Key Points: • The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. • The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. • CONQUER is innovative in its design in that it is focused on prospective collection of paired clinical and patient outcome data with bio-specimens.

AB - Abstract: The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. The data collection methodology incorporates successful models from other SSc registries. The cohort is designed to provide linked bio-specimen and clinical outcomes data on a longitudinal cohort of SSc patients for validation of hypothesis-driven research and to provide a platform for studying patient-reported outcomes in scleroderma. The CONQUER registry was developed using the guidelines of the International Society for Biological Repositories, and was an iterative process between physicians with an expertise in SSc, patient stakeholders, and information technology experts. Enrollment commenced in June 2018. During the first 6 months of the CONQUER Scleroderma study, 151 SSc patients with less than 5 years of disease duration (from first non-Raynaud’s symptom) have been recruited. The mean age is 51 ± 14 years, 83% are female, and 60% of patients have diffuse disease. Survey completion rates are above 88% for all patient-reported outcome surveys. Bio-specimen collection rates are over 97%, and disease severity score completion rates are over 98%. Pulmonary function test data is available on 91% of patients, and echocardiography is available 80%. The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. Key Points: • The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud’s symptom. • The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. • CONQUER is innovative in its design in that it is focused on prospective collection of paired clinical and patient outcome data with bio-specimens.

KW - Bio-specimens

KW - Cohort study

KW - Patient-reported outcomes

KW - Prospective study

KW - Registry

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85074696106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074696106&partnerID=8YFLogxK

U2 - 10.1007/s10067-019-04792-y

DO - 10.1007/s10067-019-04792-y

M3 - Article

C2 - 31667644

AN - SCOPUS:85074696106

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -